Sameer Ullah Khan
Research Subjects
Sameer Ullah Khan has a total of 260 co-authors. Here are the top co-authors by number of shared publications:
- Fayaz Malik
Division of Cancer Pharmacology, CSIR-Indian Institute of Integrative Medicine, Srinagar, India
11 shared publications Kaneez Fatima
Cancer Pharmacology Division, CSIR-Indian Institute of Integrative Medicine, Sanat Nagar Srinagar, 190005, Jammu and Kashmir, India
8 shared publicationsFayaz Malik
Cancer Pharmacology Division, CSIR-Indian Institute of Integrative Medicine, Sanat Nagar Srinagar, 190005, Jammu and Kashmir, India
4 shared publicationsBaseerat Hamza
Cancer Pharmacology Division, CSIR-Indian Institute of Integrative Medicine, Sanat Nagar Srinagar, 190005, Jammu and Kashmir, India
3 shared publicationsShariqa Aisha
Division of Cancer Pharmacology, CSIR-Indian Institute of Integrative Medicine, Jammu and Kashmir, India
3 shared publicationsUmed Singh
Medicinal Chemistry CSIR-Indian Institute of Integrative Medicine, Jammu, India
3 shared publications
Latest Publications
- 1 June 2024
- Published by Bentham Science Publishers Ltd. in Current Molecular Medicine
- Vol. 24 (6) , 702-711
Lavender Plant: Farming and Health Benefits
Natural remedies from a range of sources, including plants, animals, microorganisms, and marine life, have made a significant contribution to the treatment of many ailments. Lavender is a Mediterranean shrub from the Lamiaceae family. Lavender flowers (Lavandula flores) include active ingredients (3%), anthocyanins, sugars, phytosterols, minerals, and tannins and are majorly used for herbal applications. Lavender essential oil's descriptive and analytical composition varies depending on genotype, growing region, climatic circumstances, propagation, and morphological characteristics. There are around 300 chemical components in essential oil. Linalool, terpinen-4-ol, linalyl acetate, ocimene, acetate lavandulol, and cineole are the most prominent constituents. Lavender oil has antibacterial and antioxidant properties. The lavender extract helps to prevent dementia and may slow cancer cell growth, while lavender oil is used to treat skin problems. This review will cover the recent medical, economic and regional advancements in levander propagation and how the Council of Scientific & Industrial Research Indian Institute of Integrative (CSIR IIIM) aroma mission is actively acting as a bridge between farmers and their economic improvement by attracting them to the field of medicinal plant cultivation.
- 1 June 2024
- Published by Bentham Science Publishers Ltd. in Current Molecular Medicine
- Vol. 24 (6) , 702-711
Lavender Plant: Farming and Health Benefits
Natural remedies from a range of sources, including plants, animals, microorganisms, and marine life, have made a significant contribution to the treatment of many ailments. Lavender is a Mediterranean shrub from the Lamiaceae family. Lavender flowers (Lavandula flores) include active ingredients (3%), anthocyanins, sugars, phytosterols, minerals, and tannins and are majorly used for herbal applications. Lavender essential oil's descriptive and analytical composition varies depending on genotype, growing region, climatic circumstances, propagation, and morphological characteristics. There are around 300 chemical components in essential oil. Linalool, terpinen-4-ol, linalyl acetate, ocimene, acetate lavandulol, and cineole are the most prominent constituents. Lavender oil has antibacterial and antioxidant properties. The lavender extract helps to prevent dementia and may slow cancer cell growth, while lavender oil is used to treat skin problems. This review will cover the recent medical, economic and regional advancements in levander propagation and how the Council of Scientific & Industrial Research Indian Institute of Integrative (CSIR IIIM) aroma mission is actively acting as a bridge between farmers and their economic improvement by attracting them to the field of medicinal plant cultivation.
- Top Cited PapersOpen Access
- 12 February 2024
- Published by Springer Nature in Cell Communication and Signaling
- Vol. 22 (1) , 1-26
Unveiling the mechanisms and challenges of cancer drug resistance
Cancer treatment faces many hurdles and resistance is one among them. Anti-cancer treatment strategies are evolving due to innate and acquired resistance capacity, governed by genetic, epigenetic, proteomic, metabolic, or microenvironmental cues that ultimately enable selected cancer cells to survive and progress under unfavorable conditions. Although the mechanism of drug resistance is being widely studied to generate new target-based drugs with better potency than existing ones. However, due to the broader flexibility in acquired drug resistance, advanced therapeutic options with better efficacy need to be explored. Combination therapy is an alternative with a better success rate though the risk of amplified side effects is commonplace. Moreover, recent groundbreaking precision immune therapy is one of the ways to overcome drug resistance and has revolutionized anticancer therapy to a greater extent with the only limitation of being individual-specific and needs further attention. This review will focus on the challenges and strategies opted by cancer cells to withstand the current therapies at the molecular level and also highlights the emerging therapeutic options -like immunological, and stem cell-based options that may prove to have better potential to challenge the existing problem of therapy resistance.
- 12 February 2024
- Published by Springer Nature in Cell Communication and Signaling
- Vol. 22 (1) , 1-26
Top Cited PapersOpen AccessUnveiling the mechanisms and challenges of cancer drug resistance
Cancer treatment faces many hurdles and resistance is one among them. Anti-cancer treatment strategies are evolving due to innate and acquired resistance capacity, governed by genetic, epigenetic, proteomic, metabolic, or microenvironmental cues that ultimately enable selected cancer cells to survive and progress under unfavorable conditions. Although the mechanism of drug resistance is being widely studied to generate new target-based drugs with better potency than existing ones. However, due to the broader flexibility in acquired drug resistance, advanced therapeutic options with better efficacy need to be explored. Combination therapy is an alternative with a better success rate though the risk of amplified side effects is commonplace. Moreover, recent groundbreaking precision immune therapy is one of the ways to overcome drug resistance and has revolutionized anticancer therapy to a greater extent with the only limitation of being individual-specific and needs further attention. This review will focus on the challenges and strategies opted by cancer cells to withstand the current therapies at the molecular level and also highlights the emerging therapeutic options -like immunological, and stem cell-based options that may prove to have better potential to challenge the existing problem of therapy resistance.
- Open Access
- 10 October 2023
- Published by Springer Nature in Research Square
Integrative Bioinformatics Analysis of CXCR-4 (C-X-C motif chemokine receptor 4): Expression Pattern and Role in Breast Cancer Progression
C-X-C Motif Chemokine Receptor 4 (CXCR4) is a protein-coding gene that regulates the transduction of various downstream signaling cascades, which are crucial for the migration, survival, and proliferation of cancerous cells. This gene is identified as one of the highly deregulated genes in breast cancer patients. The main theme of this study was to examine the expression profile and prognostic relevance of CXCR4 among individuals with breast cancer. We examined the expression pattern, immunological relationship, gene ontology, as well as pathway involvement of CXCR4 in breast cancer (BC) using comprehensive bioinformatic approaches. The findings of our study indicate a significant upregulation of CXCR4 in BC tissues, specifically TNBC. Furthermore, there was a substantial correlation between CXCR4 and tumor stroma, specifically with regulatory T cells. The findings of this study suggest that CXCR4 plays a crucial role in the advancement of tumors. Therefore, a combined approach of targeting CXCR4 along with conventional therapies can lead to a substantial improvement in the therapeutic response of patients with BC.
- 10 October 2023
- Published by Springer Nature in Research Square
Open AccessIntegrative Bioinformatics Analysis of CXCR-4 (C-X-C motif chemokine receptor 4): Expression Pattern and Role in Breast Cancer Progression
C-X-C Motif Chemokine Receptor 4 (CXCR4) is a protein-coding gene that regulates the transduction of various downstream signaling cascades, which are crucial for the migration, survival, and proliferation of cancerous cells. This gene is identified as one of the highly deregulated genes in breast cancer patients. The main theme of this study was to examine the expression profile and prognostic relevance of CXCR4 among individuals with breast cancer. We examined the expression pattern, immunological relationship, gene ontology, as well as pathway involvement of CXCR4 in breast cancer (BC) using comprehensive bioinformatic approaches. The findings of our study indicate a significant upregulation of CXCR4 in BC tissues, specifically TNBC. Furthermore, there was a substantial correlation between CXCR4 and tumor stroma, specifically with regulatory T cells. The findings of this study suggest that CXCR4 plays a crucial role in the advancement of tumors. Therefore, a combined approach of targeting CXCR4 along with conventional therapies can lead to a substantial improvement in the therapeutic response of patients with BC.
- 20 March 2023
- Published by Springer Nature in Medical Oncology
- Vol. 40 (4) , 1-12
Small molecule ‘4ab’ induced autophagy and endoplasmic reticulum stress-mediated death of aggressive cancer cells grown under adherent and floating conditions
Metastasis is the leading cause of death in cancer patients and a major challenging aspect of cancer biology. Various adaptive molecular signaling pathways play a crucial role in cancer metastasis and later in the formation of secondary tumors. Aggressive cancer cells like triple negative breast cancer (TNBCs) are more inclined to undergo metastasis hence having a high recurrence rate and potential of micro-metastasis. Tumor cells in circulation known as circulating tumor cells (CTCs) offer an attractive drug target to treat metastatic disease. Cell cycle regulation and stress response of CTCs in blood has a crucial role in their survival and progression and thus may be considered therapeutically active hotspots. The cyclin D/cyclin-dependent kinase (CDK) pathway regulates cell cycle checkpoints, a process that is frequently dysregulated in cancer cells. Selective CDK inhibitors can limit the phosphorylation of cell cycle regulatory proteins by inducing cell cycle phase arrest, and thus may be an effective therapeutic strategy for aggressive cancer cells in their dividing phase at the primary or secondary site. However, during the floating condition, cancer cells halt their multiplication process and proceed through the various steps of metastasis. Current study showed that a novel CDK inhibitor 4ab induced autophagy and endoplasmic reticulum (ER) stress in agressive cancer cells grown under adherent and floating conditions resulting in paraptosis. Further, our results showed that 4ab efficiently induced cell death in aggressive cancer cells through ER stress-mediated activation of JNK signaling. Additionally, was observed that treatment of 4ab in tumor-bearing mice displayed a significant reduction in tumor burden and micro-metastasis. The outcome of these studies showed that 4ab can be a potential anti-tumor and anti-metastatic agent. Graphical abstract Graphical representation of 4ab: image representing the effect of 4ab on death-inducing pathways in aggressive cancer cells. 4ab induces ER stress and activates autophagy leading to vacuolation of there by causing apoptosis in aggressive cancer cells.
- 20 March 2023
- Published by Springer Nature in Medical Oncology
- Vol. 40 (4) , 1-12
Small molecule ‘4ab’ induced autophagy and endoplasmic reticulum stress-mediated death of aggressive cancer cells grown under adherent and floating conditions
Metastasis is the leading cause of death in cancer patients and a major challenging aspect of cancer biology. Various adaptive molecular signaling pathways play a crucial role in cancer metastasis and later in the formation of secondary tumors. Aggressive cancer cells like triple negative breast cancer (TNBCs) are more inclined to undergo metastasis hence having a high recurrence rate and potential of micro-metastasis. Tumor cells in circulation known as circulating tumor cells (CTCs) offer an attractive drug target to treat metastatic disease. Cell cycle regulation and stress response of CTCs in blood has a crucial role in their survival and progression and thus may be considered therapeutically active hotspots. The cyclin D/cyclin-dependent kinase (CDK) pathway regulates cell cycle checkpoints, a process that is frequently dysregulated in cancer cells. Selective CDK inhibitors can limit the phosphorylation of cell cycle regulatory proteins by inducing cell cycle phase arrest, and thus may be an effective therapeutic strategy for aggressive cancer cells in their dividing phase at the primary or secondary site. However, during the floating condition, cancer cells halt their multiplication process and proceed through the various steps of metastasis. Current study showed that a novel CDK inhibitor 4ab induced autophagy and endoplasmic reticulum (ER) stress in agressive cancer cells grown under adherent and floating conditions resulting in paraptosis. Further, our results showed that 4ab efficiently induced cell death in aggressive cancer cells through ER stress-mediated activation of JNK signaling. Additionally, was observed that treatment of 4ab in tumor-bearing mice displayed a significant reduction in tumor burden and micro-metastasis. The outcome of these studies showed that 4ab can be a potential anti-tumor and anti-metastatic agent. Graphical abstract Graphical representation of 4ab: image representing the effect of 4ab on death-inducing pathways in aggressive cancer cells. 4ab induces ER stress and activates autophagy leading to vacuolation of there by causing apoptosis in aggressive cancer cells.
- 6 December 2022
- Published by Springer Nature in Clinical and Experimental Medicine
- Vol. 23 (5) , 1405-1423
Targeting redox regulation and autophagy systems in cancer stem cells
Cancer is a dysregulated cellular level pathological condition that results in tumor formation followed by metastasis. In the heterogeneous tumor architecture, cancer stem cells (CSCs) are essential to push forward the progression of tumors due to their strong pro-tumor properties such as stemness, self-renewal, plasticity, metastasis, and being poorly responsive to radiotherapy and chemotherapeutic agents. Cancer stem cells have the ability to withstand various stress pressures by modulating transcriptional and translational mechanisms, and adaptable metabolic changes. Owing to CSCs heterogeneity and plasticity, these cells display varied metabolic and redox profiles across different types of cancers. It has been established that there is a disparity in the levels of Reactive Oxygen Species (ROS) generated in CSCs vs Non-CSC and these differential levels are detected across different tumors. CSCs have unique metabolic demands and are known to change plasticity during metastasis by passing through the interchangeable epithelial and mesenchymal-like phenotypes. During the metastatic process, tumor cells undergo epithelial to mesenchymal transition (EMT) thus attaining invasive properties while leaving the primary tumor site, similarly during the course of circulation and extravasation at a distant organ, these cells regain their epithelial characteristics through Mesenchymal to Epithelial Transition (MET) to initiate micrometastasis. It has been evidenced that levels of Reactive Oxygen Species (ROS) and associated metabolic activities vary between the epithelial and mesenchymal states of CSCs. Similarly, the levels of oxidative and metabolic states were observed to get altered in CSCs post-drug treatments. As oxidative and metabolic changes guide the onset of autophagy in cells, its role in self-renewal, quiescence, proliferation and response to drug treatment is well established. This review will highlight the molecular mechanisms useful for expanding therapeutic strategies based on modulating redox regulation and autophagy activation to targets. Specifically, we will account for the mounting data that focus on the role of ROS generated by different metabolic pathways and autophagy regulation in eradicating stem-like cells hereafter referred to as cancer stem cells (CSCs).
- 6 December 2022
- Published by Springer Nature in Clinical and Experimental Medicine
- Vol. 23 (5) , 1405-1423
Targeting redox regulation and autophagy systems in cancer stem cells
Cancer is a dysregulated cellular level pathological condition that results in tumor formation followed by metastasis. In the heterogeneous tumor architecture, cancer stem cells (CSCs) are essential to push forward the progression of tumors due to their strong pro-tumor properties such as stemness, self-renewal, plasticity, metastasis, and being poorly responsive to radiotherapy and chemotherapeutic agents. Cancer stem cells have the ability to withstand various stress pressures by modulating transcriptional and translational mechanisms, and adaptable metabolic changes. Owing to CSCs heterogeneity and plasticity, these cells display varied metabolic and redox profiles across different types of cancers. It has been established that there is a disparity in the levels of Reactive Oxygen Species (ROS) generated in CSCs vs Non-CSC and these differential levels are detected across different tumors. CSCs have unique metabolic demands and are known to change plasticity during metastasis by passing through the interchangeable epithelial and mesenchymal-like phenotypes. During the metastatic process, tumor cells undergo epithelial to mesenchymal transition (EMT) thus attaining invasive properties while leaving the primary tumor site, similarly during the course of circulation and extravasation at a distant organ, these cells regain their epithelial characteristics through Mesenchymal to Epithelial Transition (MET) to initiate micrometastasis. It has been evidenced that levels of Reactive Oxygen Species (ROS) and associated metabolic activities vary between the epithelial and mesenchymal states of CSCs. Similarly, the levels of oxidative and metabolic states were observed to get altered in CSCs post-drug treatments. As oxidative and metabolic changes guide the onset of autophagy in cells, its role in self-renewal, quiescence, proliferation and response to drug treatment is well established. This review will highlight the molecular mechanisms useful for expanding therapeutic strategies based on modulating redox regulation and autophagy activation to targets. Specifically, we will account for the mounting data that focus on the role of ROS generated by different metabolic pathways and autophagy regulation in eradicating stem-like cells hereafter referred to as cancer stem cells (CSCs).
- 1 December 2022
- Published by Bentham Science Publishers Ltd. in Combinatorial Chemistry & High Throughput Screening
- Vol. 25 (14) , 2372-2386
Myrica esculenta Buch.-Ham. (ex D. Don): A Review on its Phytochemistry, Pharmacology and Nutritional Potential
Myrica esculenta is an important ethnomedicinal plant used in the traditional system of medicine and as an important nutraceutical. Several studies on the plant justify its use in alternative systems of medicine and establish a scientific rationale for its possible therapeutic application. The plant contains a range of biologically active classes of compounds, particularly diarylheptanoids, flavonoids, terpenes, tannins, and glycosides. The nutraceutical potential of the plant can be particularly attributed to its fruit, and several studies have demonstrated the presence of carbohydrates, proteins, fats, fiber content, and minerals like sodium, potassium, calcium, manganese, iron, copper, and zinc, in it. The current review aims to provide complete insight into the phytochemistry, pharmacological potential, and nutritional potential of the plant, which would not only serve as a comprehensive source of information but also will highlight the scope of isolation and evaluation of these molecules for various disease conditions.
- 1 December 2022
- Published by Bentham Science Publishers Ltd. in Combinatorial Chemistry & High Throughput Screening
- Vol. 25 (14) , 2372-2386
Myrica esculenta Buch.-Ham. (ex D. Don): A Review on its Phytochemistry, Pharmacology and Nutritional Potential
Myrica esculenta is an important ethnomedicinal plant used in the traditional system of medicine and as an important nutraceutical. Several studies on the plant justify its use in alternative systems of medicine and establish a scientific rationale for its possible therapeutic application. The plant contains a range of biologically active classes of compounds, particularly diarylheptanoids, flavonoids, terpenes, tannins, and glycosides. The nutraceutical potential of the plant can be particularly attributed to its fruit, and several studies have demonstrated the presence of carbohydrates, proteins, fats, fiber content, and minerals like sodium, potassium, calcium, manganese, iron, copper, and zinc, in it. The current review aims to provide complete insight into the phytochemistry, pharmacological potential, and nutritional potential of the plant, which would not only serve as a comprehensive source of information but also will highlight the scope of isolation and evaluation of these molecules for various disease conditions.
- 9 November 2022
- Published by Springer Nature in Medical Oncology
- Vol. 40 (1) , 1-21
Redox balance and autophagy regulation in cancer progression and their therapeutic perspective
Cellular ROS production participates in various cellular functions but its accumulation decides the cell fate. Malignant cells have higher levels of ROS and active antioxidant machinery, a characteristic hallmark of cancer with an outcome of activation of stress-induced pathways like autophagy. Autophagy is an intracellular catabolic process that produces alternative raw materials to meet the energy demand of cells and is influenced by the cellular redox state thus playing a definite role in cancer cell fate. Since damaged mitochondria are the main source of ROS in the cell, however, cancer cells remove them by upregulating the process of mitophagy which is known to play a decisive role in tumorigenesis and tumor progression. Chemotherapy exploits cell machinery which results in the accumulation of toxic levels of ROS in cells resulting in cell death by activating either of the pathways like apoptosis, necrosis, ferroptosis or autophagy in them. So understanding these redox and autophagy regulations offers a promising method to design and develop new cancer therapies that can be very effective and durable for years. This review will give a summary of the current therapeutic molecules targeting redox regulation and autophagy for the treatment of cancer. Further, it will highlight various challenges in developing anticancer agents due to autophagy and ROS regulation in the cell and insights into the development of future therapies. Graphical Abstract
- 9 November 2022
- Published by Springer Nature in Medical Oncology
- Vol. 40 (1) , 1-21
Redox balance and autophagy regulation in cancer progression and their therapeutic perspective
Cellular ROS production participates in various cellular functions but its accumulation decides the cell fate. Malignant cells have higher levels of ROS and active antioxidant machinery, a characteristic hallmark of cancer with an outcome of activation of stress-induced pathways like autophagy. Autophagy is an intracellular catabolic process that produces alternative raw materials to meet the energy demand of cells and is influenced by the cellular redox state thus playing a definite role in cancer cell fate. Since damaged mitochondria are the main source of ROS in the cell, however, cancer cells remove them by upregulating the process of mitophagy which is known to play a decisive role in tumorigenesis and tumor progression. Chemotherapy exploits cell machinery which results in the accumulation of toxic levels of ROS in cells resulting in cell death by activating either of the pathways like apoptosis, necrosis, ferroptosis or autophagy in them. So understanding these redox and autophagy regulations offers a promising method to design and develop new cancer therapies that can be very effective and durable for years. This review will give a summary of the current therapeutic molecules targeting redox regulation and autophagy for the treatment of cancer. Further, it will highlight various challenges in developing anticancer agents due to autophagy and ROS regulation in the cell and insights into the development of future therapies. Graphical Abstract
- Open Access
- 12 October 2022
- Published by Springer Nature in Research Square
Inflated endoplasmic reticulum and autophagy induction promoted death in aggressive cancer cells grown in adherent and in-vitro CTC conditions.
Cancer metastasis is the leading cause of death in cancer patients and is a major challenging aspect of cancer biology. Various adaptive molecular signaling pathways play a crucial role in cancer metastasis and later in the formation of secondary tumors. Aggressive cancer cells like Triple Negative breast cancer (TNBCs) are more inclined to undergo metastasis hence having a high recurrence rate and potential for secondary tumor formation. Such aggressive cancer cells have fewer treatment options available with poor prognoses. Metastatic cells in circulation known as circulating tumor cells (CTCs) could be an appealing alternative target for cancer therapy with potentially better outcomes. Cell cycle regulation and stress response of CTCs in blood has a crucial role in their survival and progression and thus may be considered therapeutically active hotspots. The cyclin D/cyclin-dependent kinase (CDK) pathway regulates cell cycle checkpoints, a process that is frequently dysregulated in cancer cells. Selective CDK inhibitors can limit the phosphorylation of cell cycle regulatory proteins by inducing cell cycle phase arrest, and thus may be an effective therapeutic strategy for aggressive cancer cells in their dividing phase at the primary or secondary site. However, during the floating condition, cancer cells halt their division process and proceed through the various steps of metastasis. Our study showed that a novel CDK inhibitor 4ab besides showing anti-proliferative activity in aggressive cancer cells also induces cell death by activating endoplasmic reticulum stress and strong autophagy induction in both adherent and floating conditions which resulted in cytoplasmic vacuolation (paraptosis) and ultimately resulted in cell death. Further our results showed that 4ab efficiently induced apoptosis in aggressive cancer cells by initiating the ER-mitochondrial membrane potential loss-JNK pathway. Further, our in vivo data showed a promising inhibitory effect of 4ab on aggressive 4T1 cells in tumor formation and metastasis. The above data gave us encouraging results to consider 4ab as a potential inhibitor for anti-metastatic therapeutic intervention.
- 12 October 2022
- Published by Springer Nature in Research Square
Open AccessInflated endoplasmic reticulum and autophagy induction promoted death in aggressive cancer cells grown in adherent and in-vitro CTC conditions.
Cancer metastasis is the leading cause of death in cancer patients and is a major challenging aspect of cancer biology. Various adaptive molecular signaling pathways play a crucial role in cancer metastasis and later in the formation of secondary tumors. Aggressive cancer cells like Triple Negative breast cancer (TNBCs) are more inclined to undergo metastasis hence having a high recurrence rate and potential for secondary tumor formation. Such aggressive cancer cells have fewer treatment options available with poor prognoses. Metastatic cells in circulation known as circulating tumor cells (CTCs) could be an appealing alternative target for cancer therapy with potentially better outcomes. Cell cycle regulation and stress response of CTCs in blood has a crucial role in their survival and progression and thus may be considered therapeutically active hotspots. The cyclin D/cyclin-dependent kinase (CDK) pathway regulates cell cycle checkpoints, a process that is frequently dysregulated in cancer cells. Selective CDK inhibitors can limit the phosphorylation of cell cycle regulatory proteins by inducing cell cycle phase arrest, and thus may be an effective therapeutic strategy for aggressive cancer cells in their dividing phase at the primary or secondary site. However, during the floating condition, cancer cells halt their division process and proceed through the various steps of metastasis. Our study showed that a novel CDK inhibitor 4ab besides showing anti-proliferative activity in aggressive cancer cells also induces cell death by activating endoplasmic reticulum stress and strong autophagy induction in both adherent and floating conditions which resulted in cytoplasmic vacuolation (paraptosis) and ultimately resulted in cell death. Further our results showed that 4ab efficiently induced apoptosis in aggressive cancer cells by initiating the ER-mitochondrial membrane potential loss-JNK pathway. Further, our in vivo data showed a promising inhibitory effect of 4ab on aggressive 4T1 cells in tumor formation and metastasis. The above data gave us encouraging results to consider 4ab as a potential inhibitor for anti-metastatic therapeutic intervention.
- 13 July 2022
- Published by Springer Nature in Clinical & Experimental Metastasis
- Vol. 39 (5) , 715-726
Understanding the cell survival mechanism of anoikis-resistant cancer cells during different steps of metastasis
Anchorage-independent survival of cancer cells is associated with metastasis as it enables cells to travel to secondary target sites. Tissue integrity is generally maintained by detachment-induced cell death called ‘anoikis’, but cancer cells undergoing the multistep metastatic process show resistance to anoikis. Anoikis resistance enables these cells to survive through the extracellular matrix (ECM) deprived phase, which starts when cancer cells detach and move into the circulation till cells reach to the secondary target site. Comprehensive analysis of the molecular and functional biology of anoikis resistance in cancer cells will provide crucial details about cancer metastasis, enabling us to identify novel therapeutic targets against cancer cell dissemination and ultimately secondary tumor formation. This review broadly summarizes recent advances in the understanding of cellular and molecular events leading to anoikis and anoikis resistance. It further elaborates more about the signaling cross-talk in anoikis resistance and its regulation during metastasis.
- 13 July 2022
- Published by Springer Nature in Clinical & Experimental Metastasis
- Vol. 39 (5) , 715-726
Understanding the cell survival mechanism of anoikis-resistant cancer cells during different steps of metastasis
Anchorage-independent survival of cancer cells is associated with metastasis as it enables cells to travel to secondary target sites. Tissue integrity is generally maintained by detachment-induced cell death called ‘anoikis’, but cancer cells undergoing the multistep metastatic process show resistance to anoikis. Anoikis resistance enables these cells to survive through the extracellular matrix (ECM) deprived phase, which starts when cancer cells detach and move into the circulation till cells reach to the secondary target site. Comprehensive analysis of the molecular and functional biology of anoikis resistance in cancer cells will provide crucial details about cancer metastasis, enabling us to identify novel therapeutic targets against cancer cell dissemination and ultimately secondary tumor formation. This review broadly summarizes recent advances in the understanding of cellular and molecular events leading to anoikis and anoikis resistance. It further elaborates more about the signaling cross-talk in anoikis resistance and its regulation during metastasis.
- Open Access
- 25 April 2022
- Published by Elsevier in Computers in Biology and Medicine
- Vol. 146, 105419
A machine learning-based approach to determine infection status in recipients of BBV152 (Covaxin) whole-virion inactivated SARS-CoV-2 vaccine for serological surveys
- 25 April 2022
- Published by Elsevier in Computers in Biology and Medicine
- Vol. 146, 105419
Open AccessA machine learning-based approach to determine infection status in recipients of BBV152 (Covaxin) whole-virion inactivated SARS-CoV-2 vaccine for serological surveys